Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from ...
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Seeking Alpha on MSN17h
Incyte seesaws on report of potential Merck takeover interestIncyte (NASDAQ:INCY) shares seesawed and are now down 10% amid a posting about potential takeover speculation from Merck ...
Shares of Merck & Co. Inc. MRK dropped 0.02% to $96.54 Tuesday, on what proved to be an all-around mixed trading session ...
Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting ...
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Warren Buffett was a net seller of stocks for the eighth consecutive quarter in Q3. Berkshire initiated new positions in only ...
Merck (MRK) declared a quarterly dividend of 81c per share of the company’s common stock for Q1 of 2025. Payment will be made on January 8, ...
In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck (MRK), the US-listed pharma group, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback